Projekt

An open-label, randomized, multi-center, Phase III study to compare the safety and efficacy of TKI258 versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies

Automatisch geschlossen · 2011 bis 2013

Rothermundt Christian, Gillessen Sommer Silke